Novo Nordisk Faces a Legal Double Header as Earnings Approach
The Danish pharmaceutical heavyweight is fighting on two legal fronts just days before a pivotal earnings report, with…
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
Novo Nordisk A/S A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which…
Novo Nordisk Takes Lilly to Court Over GLP-1 Ad Claims as Market Share Battle Intensifies
Novo Nordisk has escalated its legal confrontation with Eli Lilly, filing for a preliminary injunction in a New…
Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race
Novo is also seeking a permanent injunction requiring Lilly to withdraw the campaigns and publish corrective advertisements The…
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
Novo Nordisk A/S A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which…
Weight-loss wars: Why Novo Nordisk is suing Eli Lilly
00:00 Speaker A Novo Nordisk is filing a suit against Eli Lilly today and it has to do…
Weight-loss drug wars escalate as Novo Nordisk targets Eli Lilly ads in lawsuit
Novo Nordisk A/S sued Eli Lilly & Co., accusing its rival of misleading advertising as competition in the…
Novo Nordisk Deploys Multipronged Counteroffensive as Eli Lilly Gains Ground
Novo Nordisk is fighting back on multiple fronts as its rival Eli Lilly tightens its grip on the…
Novo Nordisk Fires Back on Multiple Fronts as Eli Lilly Eats Into Market Share
Novo Nordisk is racing to defend its weight-loss empire on three continents simultaneously, rolling out the oral version…
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Foundayo is already approved by the FDA for obesity. Lilly said it plans to submit Foundayo for U.S.…
An Analyst Just Declared Eli Lilly the “Clear Winner” of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo’s Chief Scientist Disagrees. Who’s Right?
Key Points “The field is getting more crowded — but Lilly is widening its lead,” said RBC analyst…
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
Quick Read LLY grew revenue 56% and raised guidance to a range of $82B to $85B, while NVO…